27 results about "Micronazole" patented technology

The invention provides a hybridoma cell strain secreting a clotrimazole monoclonal antibody and application of the hybridoma cell strain, and relates to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to clotrimazole, the IC50 value of clotrimazole is 7.386 ng / mL, and the monoclonal antibody has good sensitivity; moreover, the clotrimazole monoclonal antibody has no cross reaction on functional analogues of clotrimazole, such as miconazole, econazole, ketoconazole, bifonazole and sertaconazole, and has good specificity. Therefore, the clotrimazole monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention can be used for accurately detecting low-concentration clotrimazole.

The invention relates to the technical field of biological medicine, in particular to application of a stable silicic acid aqueous solution in preparation of a product for treating war wound infection, and the mass concentration of the stable silicic acid aqueous solution is 0.5%-2%. The product taking the stable silicic acid aqueous solution as the active ingredient can be used for treating war wound infection or cryptococcus gattii infection, can resist cryptococcus gattii infection at the mass concentration of 0.5-2%, and has the effect of resisting war wound infection, and meanwhile, the stable silicic acid aqueous solution is low in raw material cost, environment-friendly, safe and suitable for industrial production. The compound can be used as a substitute medicine of a traditional medicine miconazole with a good curative effect.

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

The present invention relates to the technical field of veterinary drugs, and more particularly, to a composition for treating a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01-10):(0.1-20):(0.1-5), and a mixed solvent containing water and glycerin in which the main active ingredients are soluble. The composition possesses significant curative effects on fungal infections on the skin surfaces of animals, with low toxicity and low irritation.

The application provides a hybridoma cell strain secreting a monoclone antibody of clotrimazole and application thereof, and relates to the technical field of immune detection. The monoclone antibody secreted by the hybridoma cell strain has good sensitivity and specificity to clotrimazole, wherein the IC 50 value of clotrimazole is 7.386 ng / mL, and the monoclone antibody has good sensitivity; and the monoclone antibody has no cross reaction to functional analogues of clotrimazole, such as miconazole, econazole, ketoconazole, bifonazole and sertaconazole, and has good specificity. Therefore, the monoclone antibody of clotrimazole secreted by the hybridoma cell strain can accurately detect low-concentration clotrimazole.

The application discloses a series of afluconazole derivatives or pharmaceutically acceptable inorganic salts, organic salts and solvates thereof. The application also discloses a preparation method of the afluconazole derivatives and application of the afluconazole derivatives in preparation of medicines for treating or preventing fungal infections. Experimental results show that the preliminary in-vitro antifungal activity of the target compounds is obviously better than that of afluconazole and other currently widely used azole antifungal medicines (such as miconazole, fluconazole and oterconazole), the water solubility of the target compounds is better, the antibacterial spectrum is wider, the activity is higher, the pharmacokinetic properties are better, and the target compounds have further development potential.

The invention provides miconazole nitrate emulsifiable paste and a preparation process, and belongs to the technical field of external medicines, and the miconazole nitrate emulsifiable paste is characterized by comprising the following components in parts by mass: 1.8-2.0 wt% of miconazole nitrate, 0.3-2.0 wt% of an allantoin eugenol amide ester penetration enhancer, 3-5 wt% of medium-chain triglyceride, 5-10 wt% of glycerin monostearate, 8-15 wt% of white vaseline, 6-12 wt% of glycerol and the balance of water. The cleaning agent is prepared from, by weight, 0.01%-0.10% of bis (hydroxymethyl) imidazolidinyl urea, 6%-12% of octadecanol, 1%-3% of triethanolamine and the balance purified water. The preparation process comprises the steps of preparation of cream, homogenization of miconazole nitrate emulsion and preparation of the miconazole nitrate cream. According to the invention, the nanoscale miconazole nitrate cream product with uniform and fine texture is prepared from the aspects of drug particle size optimization and homogenization; the added allantoin eugenol amide ester penetration enhancer is safe and non-irritant, and when the allantoin eugenol amide ester penetration enhancer and miconazole nitrate are used together, penetration of the ointment is promoted, and skin recovery is accelerated; meanwhile, the problems of yellowing, deterioration and the like of the cream can be effectively prevented.

The present application relates to the technical field of pharmaceutical formulations, and particularly relates to a compound miconazole nitrate lotion and a preparation process thereof, which comprises the following raw materials in percentage by weight: miconazole nitrate 1.5-2.5%, amphiphilic polymer 5-6%, chlorhexidine gluconate 1.5-2.5%, casone 0.05-0.1%, benzoic acid 0.1-0.2%, surfactant 25-32%, PEG-120 methyl glucose dioleate 1-2%, citric acid monohydrate 0.3-0.4%, and sodium chloride 0.7-0.9%, and the rest is water. The compound miconazole nitrate lotion prepared by the present application has dual effects of anti-fungus and antibiosis, expands the scope of indications, enhances the overall antibacterial effect of the lotion, and is suitable for the treatment and prevention of various skin infections.

The invention discloses an open-type cold region Chinese rose tissue culture seedling propagation method, which is characterized in that parachlorometaxylenol and miconazole nitrate are used as bacteriostatic agents and are respectively applied to tissue culture links such as explant earlier-stage treatment, appliance sterilization, culture medium preparation, explant disinfection, tissue culture seedling transplanting and the like, so that the propagation process of the cold region Chinese rose tissue culture seedling gets rid of environmental limitation. Explant disinfection does not need a strict sterile environment, a high-pressure sterilization pot and an ultra-clean workbench are not used, and rapid breeding of Chinese rose tissue culture seedlings is achieved. Compared with a conventional sterilization method, the induction rate of the cluster buds is remarkably improved, and the pollution rate, the vitrification rate and the browning rate are remarkably reduced. The growth vigor of the tissue culture seedlings after rooting is obviously improved; and particularly, the effects of Hanjin No.1 and Changbai Mountain vine roses are prominent.

The invention establishes a high performance liquid chromatography analysis method for measuring benzoic acid in miconazole nitrate cream, and the method has the advantages of strong specificity, high sensitivity and accuracy, and good repeatability and durability. Chromatographic conditions are as follows: an HPLC (High Performance Liquid Chromatography) system is a simerflight U3000 high performance liquid chromatograph (UV / DAD detector) or similar equipment; a chromatographic column is a chromatographic column taking octadecylsilane chemically bonded silica as a filling agent; the mobile phase consists of A, B and C; wherein A is a phosphate buffer solution, B is acetonitrile, and C is methanol. In addition, the concentration of phosphate in the phosphate buffer solution is 0.05 mol / L, and the pH is adjusted to be 3.5-4.0; the volume ratio of A to B to C is in the range of (40-50): 35: (15-25); the detection wavelength is 230 nm; the sample size is 10 microliters; the column temperature is 30 DEG C; the flow velocity is 1.0 ml / min.

1. Name of the Design Product: Packaging Bottle (Compound Miconazole Nitrate Lotion). 2. Use of the Design Product: The design product is used for packaging products. 3. Design Key Points of the Design Product: The combination of shape, pattern and color. 4. Picture or Photograph Best Showing the Design Key Points: Front View. 5. The claimed design includes color.

The present invention provides a topical pharmaceutical formulation comprising a combination of miconazole or a pharmaceutically acceptable salt thereof and domiphen bromide, a formulation vehicle and a viscosity modifier; wherein the ratio of w / w% miconazole (salt) to w / w% domiphen bromide is between 6 to 20 endpoints included and wherein the amount of viscosity modifier is sufficient to adjust the viscosity of the topical formulation to a value of 1000-4600 mPa.s measured at 25°C. The invention further provides use of said formulation in a treatment of vaginal Candida (biofilm) infections, wherein once daily use of 4.5-5.5 g of the formulation for a duration of 7 days performed better than a reference product and unexpectedly also performed better than a formulation with a double domiphen bromide dose. Improved performance was the relapse prevention for a duration of at least 28 days in human patients treated for a vulvovaginal Candida (biofilm) infection.

The invention discloses a method for detecting matrix components in a miconazole nitrate suppository, which adopts HPLC-ELSD detection and specifically comprises the following steps: 1) preparing a reference solution; 2) preparing a test solution; 3) respectively drawing the reference solution and the test solution and injecting them into a high performance liquid chromatograph. The method for detecting matrix components in the miconazole nitrate suppository of the invention completely separates the matrix components of the miconazole nitrate suppository in a chromatogram through a specific sample pretreatment method and chromatographic conditions, and provides a new method for analyzing the composition of the matrix components of the miconazole nitrate suppository.

The invention relates to a hybridoma cell strain secreting an isavuconazole monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the isavuconazole, the IC50 value of the monoclonal antibody to the isavuconazole is 13.317 ng / mL, and the IC50 value of the monoclonal antibody to the structural analogue of the isavuconazole is 13.317 ng / mL. According to the present invention, the low-concentration isavuconazole, such as fluconazole, ketoconazole, posaconazole, clotrimazole, miconazole, econazole, voriconazole, bifenconazole, luliconazole and sertaconazole, does not have the cross reaction, and the cross reaction rate is less than 1%, such that the low-concentration isavuconazole can be accurately detected.

1. The name of the design product: packaging box of imidazole nitrate liniment. 2. The use of the design product: for packaging imidazole nitrate liniment. 3. The design points of the design product: in the pattern. 4. The picture or photo that best indicates the design points: front view.

Compositions and methods for the treatment of onychomycosis. The compositions include a pharmaceutically effective amount of one or more anti-fungal agents in a petrolatum carrier. The one or more anti-fungal agents may include, for example, terbinafine HCl, ciclopirox, ciclopirox olamine, fluconazole, itraconazole, ketoconazole, amorolfine, efinaconazole, clotrimazole, miconazole (miconazole nitrate), and any combination thereof.

The application provides a miconazole nitrate cream and a preparation process, and belongs to the technical field of external medicines, and is characterized in that the miconazole nitrate cream comprises the following components in terms of mass fraction: 1.8wt-2.0wt% miconazole nitrate, 0.3wt-2.0wt% allantoin eugenol amide ester penetration enhancer, 3wt%-5wt% medium-chain triglyceride, 5wt%-10wt% glycerol monostearate, 8wt%-15wt% white petrolatum, 6wt-12wt% glycerol, 0.01wt%-0.10wt% bis(hydroxymethyl)imidazole alkyl urea, 6wt%-12wt% octadecanol, 1wt%-3wt% triethanolamine, and the balance is purified water. The preparation process comprises cream preparation, miconazole nitrate emulsion homogenization and miconazole nitrate cream preparation. The application prepares a nano miconazole nitrate cream product with uniform and delicate texture from the aspects of drug particle size optimization and homogenization. The added allantoin eugenol amide ester penetration enhancer is safe and non-irritating, and the use of the miconazole nitrate cream not only promotes the penetration of the cream and accelerates the recovery of the skin, but also has certain antioxidant function and can effectively prevent the cream from yellowing and deteriorating.

The present invention relates to the technical field of veterinary drugs, in particular to a composition for treating a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01-10):(0.1-20):(0.1-5), and a mixed solvent of water and glycerin in which the main active ingredients are soluble. The composition has a significant curative effect on fungal infections on the skin surfaces of animals, with low toxicity and low irritation.

The present invention relates to the technical field of veterinary medicinal products, in particular a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a mixed solvent of water and dimethylacetamide in which the main active ingredients are soluble. The composition has a significant curative effect on fungal infections on the skin surface of animals, with low toxicity and minimal irritation.

The purpose of the present application is to provide: an enhancer of radiation sensitivity of cancer cells such as prostate cancer cells; and others. The present application discloses, as one embodiment of the invention, an Artemis inhibitor that contains a miconazole compound as an active ingredient.

This invention discloses a method and application for the determination of multiple components based on HPLC dual-wavelength gradient elution. The method includes: setting chromatographic conditions; using octadecylsilane-bonded silica gel as the packing material and acetonitrile-0.5% triethylamine solution as the mobile phase; preparing a mixed reference solution, a test solution, and a negative sample solution; accurately injecting the solutions into the HPLC instrument; determining and recording the chromatograms according to the chromatographic conditions; calculating the content based on peak area using the external standard method; and performing linear regression on the peak area y with the solution's mass concentration x. The HPLC dual-wavelength gradient elution method established in this invention can simultaneously determine the content of four components—chloramphenicol, diphenhydramine hydrochloride, clobetasol propionate, and miconazole nitrate—in imipramine cream. It exhibits strong specificity, good linearity, good precision and repeatability, and high recovery rate, improving quality control standards and comprehensively evaluating the overall quality of the product.

The invention relates to a hybridoma cell strain secreting an isavuconazole monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the isavuconazole, the IC50 value of the monoclonal antibody to the isavuconazole is 13.317 ng / mL, and the IC50 value of the monoclonal antibody to the structural analogue of the isavuconazole is 13.317 ng / mL. According to the present invention, the low-concentration isavuconazole, such as fluconazole, ketoconazole, posaconazole, clotrimazole, miconazole, econazole, voriconazole, bifenconazole, luliconazole and sertaconazole, does not have the cross reaction, and the cross reaction rate is less than 1%, such that the low-concentration isavuconazole can be accurately detected.

1. Name of the product in this design: Packaging Kit (Miconazole Nitrate Cream). 2. Purpose of this design: for packaging and holding items. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design points: 3D model of Kit 1. 5. Other situations requiring explanation: Kit description: Kit 1 is the outer packaging box, and Kit 2 is the inner packaging tube.

The invention relates to the technical field of medicine formulas, in particular to a compound miconazole nitrate lotion and a preparation process thereof. The invention discloses a miconazole nitrate water dispersible granule, which is prepared from the following raw materials in percentage by weight: 1.5 to 2.5 percent of miconazole nitrate, 5 to 6 percent of amphiphilic polymer, 1.5 to 2.5 percent of chlorhexidine gluconate, 0.05 to 0.1 percent of kathon, 0.1 to 0.2 percent of benzoic acid, 25 to 32 percent of surfactant, 1 to 2 percent of PEG-120 methyl glucose dioleate, 0.3 to 0.4 percent of citric acid monohydrate, 0.7 to 0.9 percent of sodium chloride and the balance of water. The compound miconazole nitrate lotion prepared by the invention has dual effects of resisting fungi and bacteria, widens the range of indications, enhances the overall antibacterial effect of the lotion, and is suitable for treating and preventing various skin infections.

The invention relates to a compound antibacterial spray for pets as well as a preparation method and application of the compound antibacterial spray. Comprising the following preparation raw materials in percentage by mass: 3-7% of chlorhexidine gluconate, 3-8% of miconazole nitrate, 3-8% of ivermectin, 5-10% of glycerol, 2-8% of a carboxymethyl cellulose solution, 12-18% of modified mesoporous silicon, 5-10% of jojoba oil, 0.1-2% of Tween 80, 1-3% of oil-soluble azone, 8-15% of absolute ethyl alcohol and 35-45% of purified water. Wherein the modified mesoporous silicon is obtained after modification of D-cysteine and / or polyethyleneimine. The preparation method comprises the following steps: loading chlorhexidine gluconate, miconazole nitrate, ivermectin, jojoba oil, Tween 80 and oil-soluble azone on modified mesoporous silicon prepared by modifying D-cysteine and / or polyethyleneimine in a multi-layer form, coating with carboxymethyl cellulose, and mixing with absolute ethyl alcohol and purified water to obtain the compound antibacterial spray for pets. The compound antibacterial spray for pets can realize a lasting antibacterial function and is relatively good in storage stability.

Disclosed in the present invention are a series of efinaconazole derivatives or pharmaceutically acceptable inorganic salts, organic salts, solvates, optical isomers or polymorphs thereof. Also disclosed are a preparation method therefor and a use of these efinaconazole derivatives in the preparation of a drug for the treatment or prevention of fungal infection. Experimental results have shown that a plurality of target compounds exhibit significantly better preliminary in vitro antifungal activity than the lead compound efinaconazole and other azole antifungal drugs widely used clinically at present (such as miconazole, fluconazole, and oteseconazole), show relatively good water solubility, a wide antifungal spectrum, high activity, and good pharmacokinetic properties, and have further research and development potential.

The utility model relates to the field of miconazole nitrate processing, in particular to a miconazole nitrate processing device. The miconazole nitrate processing device provided by the utility model has the beneficial effects that in the miconazole nitrate processing and producing process, a worker can conveniently control the grinding degree of grinding miconazole nitrate raw materials into powder. According to the technical scheme, the miconazole nitrate processing device comprises a material placing base and sliding rods fixedly connected to the left side and the right side of the upper portion of the material placing base, a lifting frame is connected to the two sliding rods in a sliding mode, a rotating rod is rotationally connected to the middle of the lifting frame, a supporting plate is fixedly connected to the bottom of the rotating rod, and the supporting plate is fixedly connected to the supporting plate. The bottom of the supporting plate is fixedly connected with a transverse rod, the left side and the right side of the transverse rod are each rotationally connected with a grinding wheel, the front side and the rear side of the bottom of the material containing base are each fixedly connected with a supporting frame, and grinding discs are placed on the two supporting frames.